Trial Profile

An Expanded Access Program for Retinitis Pigmentosa in Adults Aged 18 Years and Older

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OCU 400 (Primary)
Indications Retinitis pigmentosa
Focus Expanded access; Therapeutic Use

Most Recent Events

08 Aug 2024 New trial record
05 Aug 2024 According to an Ocugen media release, the United States Food and Drug Administration (FDA) notified Ocugen, Inc. to begin its expanded access program (EAP) for the treatment of patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com